` ITCI (Intra-Cellular Therapies Inc) vs S&P 500 Comparison - Alpha Spread

ITCI
vs
S&P 500

Over the past 12 months, ITCI has significantly outperformed S&P 500, delivering a return of 102% compared to the S&P 500's 12% growth.

Stocks Performance
ITCI vs S&P 500

Loading
ITCI
S&P 500
Add Stock

Performance Gap
ITCI vs S&P 500

Loading
ITCI
S&P 500
Difference

Performance By Year
ITCI vs S&P 500

Loading
ITCI
S&P 500
Add Stock

Competitors Performance
Intra-Cellular Therapies Inc vs Peers

S&P 500
ITCI
LLY
JNJ
NOVO B
ROG
Add Stock

Intra-Cellular Therapies Inc
Glance View

Economic Moat
Narrow
Market Cap
14B USD
Industry
Pharmaceuticals

Intra-Cellular Therapies Inc., founded in 2002, finds itself at the intersection of scientific innovation and commercial success. This biopharmaceutical company is built around the vision of translating ground-breaking discoveries in neuroscience into important medications for serious neuropsychiatric and neurological disorders. The firm’s flagship product, CAPLYTA (lumateperone), exemplifies its dedication to comprehensive central nervous system solutions. Approved by the FDA for the treatment of schizophrenia in adults, and later approved for bipolar depression, CAPLYTA positions Intra-Cellular Therapies within a competitive landscape of mental health treatments. It is through pharmaceutical sales of CAPLYTA that Intra-Cellular Therapies generates revenue, capitalizing on extensive research to carve out a niche in a market with significant medical needs. Operating predominantly in the United States, Intra-Cellular Therapies harnesses its proprietary technologies, including PDE1 inhibition and other novel mechanisms of action, to pioneer treatments aimed at improving patients' quality of life. The company invests heavily in research and development, fueled by its robust clinical pipeline that constantly explores new therapeutic opportunities. Their approach involves not just the development of medications but also extensive engagement with healthcare providers and thought leaders to better understand and serve the patient community. This strategy underscores a business model where innovation directly translates to market viability, as the company embarks on long-term growth through the expansion of indications for its existing drugs and exploration of new compounds.

ITCI Intrinsic Value
89.56 USD
Overvaluation 32%
Intrinsic Value
Price
Back to Top